Amyotrophic lateral sclerosis diagnostic study of choice: Difference between revisions
Jump to navigation
Jump to search
Tooba Kashif (talk | contribs) |
Tooba Kashif (talk | contribs) |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}}{{MMJ}} | {{CMG}}; {{AE}}{{MMJ}} | ||
== Overview == | == Overview == | ||
ALS is a clinical diagnosis. Due to the absence of any disease bio-markers, the presence of both UMN and LMN signs and symptoms in the same body region along with the progression of these symptoms. Modified ''El-Escorial'' diagnostic criteria are used for elucidation of electrophysiological changes for the diagnosis of ALS. El- Escorial criteria are also known as ''Airlie House recommendations''. It was revised in a meeting at Awaji Island, Japan in 2006. Current Airlie house recommendations were revised step by step. Awaji criteria have a significant impact on the diagnosis of ALS. | ALS is a clinical diagnosis. Due to the absence of any disease bio-markers, the presence of both UMN and LMN signs and symptoms in the same body region along with the progression of these symptoms. Modified ''El-Escorial'' diagnostic criteria are used for elucidation of electrophysiological changes for the diagnosis of ALS. El- Escorial criteria are also known as ''Airlie House recommendations''. It was revised in a meeting at Awaji Island, Japan in 2006. Current Airlie house recommendations were revised step by step. Awaji criteria have a significant impact on the early diagnosis of ALS. Currently, Gold coast criteria are used for the diagnosis of ALS. | ||
== Diagnostic Study of Choice == | == Diagnostic Study of Choice == | ||
=== | === Name of Diagnostic Criteria === | ||
* | * Awaji Criteria for the diagnosis of ALS was proposed to facilitate the diagnosis of ALS in the early stage. | ||
Major points include: | |||
* Electromyography is considered equivalent to the clinical examination of the identification for LMN signs and fasciculations. | |||
<ref name="pmid23261262">{{cite journal| author=Guennoc AM, Camu W, Corcia P| title=[Awaji criteria: new diagnostic criteria for amyotrophic lateral sclerosis]. | journal=Rev Neurol (Paris) | year= 2013 | volume= 169 | issue= 6-7 | pages= 470-5 | pmid=23261262 | doi=10.1016/j.neurol.2012.10.007 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23261262 }} </ref> | |||
* | *Both Awaji and El-escorial criteria are complicated to apply for the diagnosis of ALS and also prone to errors. | ||
* | * For all these reasons '''Gold coast criteria'' were established to modify the existing criteria and to simplify the diagnosis of ALS. | ||
Key points of Gold coast criteria are: | |||
1. Progressive motor degeneration documented by history/repeated clinical evaluation, with previously normal motor function, and | |||
2. Presence of upper and lower motor neuron dysfunction in at least one body region, (with upper and lower motor neuron dysfunction noted in the same body region) or lower motor neuron dysfunction in at least two body regions, and | |||
3. Key Investigations (EMG, imaging, etc) that exclude other disease processes. | |||
<ref name="pmid32387049">{{cite journal| author=Shefner JM, Al-Chalabi A, Baker MR, Cui LY, de Carvalho M, Eisen A | display-authors=etal| title=A proposal for new diagnostic criteria for ALS. | journal=Clin Neurophysiol | year= 2020 | volume= 131 | issue= 8 | pages= 1975-1978 | pmid=32387049 | doi=10.1016/j.clinph.2020.04.005 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32387049 }} </ref> | |||
==References== | ==References== | ||
Latest revision as of 16:46, 15 September 2021
|
Amyotrophic lateral sclerosis Microchapters |
|
Differentiating Amyotrophic lateral sclerosis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Amyotrophic lateral sclerosis diagnostic study of choice On the Web |
|
American Roentgen Ray Society Images of Amyotrophic lateral sclerosis diagnostic study of choice |
|
FDA on Amyotrophic lateral sclerosis diagnostic study of choice |
|
CDC on Amyotrophic lateral sclerosis diagnostic study of choice |
|
Amyotrophic lateral sclerosis diagnostic study of choice in the news |
|
Blogs on Amyotrophic lateral sclerosis diagnostic study of choice |
|
Risk calculators and risk factors for Amyotrophic lateral sclerosis diagnostic study of choice |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamadmostafa Jahansouz M.D.[2]
Overview
ALS is a clinical diagnosis. Due to the absence of any disease bio-markers, the presence of both UMN and LMN signs and symptoms in the same body region along with the progression of these symptoms. Modified El-Escorial diagnostic criteria are used for elucidation of electrophysiological changes for the diagnosis of ALS. El- Escorial criteria are also known as Airlie House recommendations. It was revised in a meeting at Awaji Island, Japan in 2006. Current Airlie house recommendations were revised step by step. Awaji criteria have a significant impact on the early diagnosis of ALS. Currently, Gold coast criteria are used for the diagnosis of ALS.
Diagnostic Study of Choice
Name of Diagnostic Criteria
- Awaji Criteria for the diagnosis of ALS was proposed to facilitate the diagnosis of ALS in the early stage.
Major points include:
- Electromyography is considered equivalent to the clinical examination of the identification for LMN signs and fasciculations.
- Both Awaji and El-escorial criteria are complicated to apply for the diagnosis of ALS and also prone to errors.
- For all these reasons 'Gold coast criteria were established to modify the existing criteria and to simplify the diagnosis of ALS.
Key points of Gold coast criteria are:
1. Progressive motor degeneration documented by history/repeated clinical evaluation, with previously normal motor function, and
2. Presence of upper and lower motor neuron dysfunction in at least one body region, (with upper and lower motor neuron dysfunction noted in the same body region) or lower motor neuron dysfunction in at least two body regions, and
3. Key Investigations (EMG, imaging, etc) that exclude other disease processes.
References
- ↑ Guennoc AM, Camu W, Corcia P (2013). "[Awaji criteria: new diagnostic criteria for amyotrophic lateral sclerosis]". Rev Neurol (Paris). 169 (6–7): 470–5. doi:10.1016/j.neurol.2012.10.007. PMID 23261262.
- ↑ Shefner JM, Al-Chalabi A, Baker MR, Cui LY, de Carvalho M, Eisen A; et al. (2020). "A proposal for new diagnostic criteria for ALS". Clin Neurophysiol. 131 (8): 1975–1978. doi:10.1016/j.clinph.2020.04.005. PMID 32387049 Check
|pmid=value (help).